The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed an amended beneficial ownership statement with the SEC on November 9, 2026, reporting zero beneficial ownership of ordinary shares of TNL Mediagene as of September 30, 2026.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a joint Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of common stock in Pacific Biosciences of California, Inc. as of September 30, 2026.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a joint Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of approximately 5.9% of Oxford Industries, Inc. common stock as of September 30, 2026.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a joint Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of ordinary shares of Range Capital Acquisition Corp as of September 30, 2026.
GS Finance Corp. filed a Free Writing Prospectus on November 9, 2026, disclosing terms for Market Linked Securities that are autocallable with a fixed percentage buffered downside, linked to the EURO STOXX 50 Index and due November 26, 2029.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a joint Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of approximately 5.9% of Tandem Diabetes Care, Inc. common stock as of September 30, 2026.
First Advantage Corporation filed a free writing prospectus on November 9, 2026, announcing that Silver Lake Group, L.L.C. and its affiliates intend to sell 15,000,000 shares of First Advantage common stock in an underwritten secondary offering.
McDonald's Corporation filed a free writing prospectus on November 9, 2026, disclosing the pricing terms of two tranches of SEC-registered senior unsecured fixed-rate medium-term notes totaling USD 1,200,000,000, with settlement expected on November 17, 2026.
Novartis Capital Corporation filed a free writing prospectus on November 9, 2026, disclosing pricing terms for a four-tranche U.S. dollar-denominated notes offering totaling $5,250,000,000, fully and unconditionally guaranteed by Novartis AG.
JATT II Acquisition Corp. filed a definitive proxy statement and prospectus on November 9, 2026, asking shareholders to approve a business combination with Talawar Tx Inc. under a Business Combination Agreement dated June 29, 2026.